Mutations associated with acquired resistance to PD-1 blockade in melanoma

New England Journal of Medicine

Volumn 375, Issue 9, 2016, Pages 819-829

  Zaretsky, Jesse M ^a   Garcia Diaz, Angel ^a   Shin, Daniel S ^a   Escuin Ordinas, Helena ^a   Hugo, Willy ^a   Hu Lieskovan, Siwen ^a   Torrejon, Davis Y ^a   Abril Rodriguez, Gabriel ^a   Sandoval, Salemiz ^a   Barthly, Lucas ^a   Saco, Justin ^a   Moreno, Blanca Homet ^a   Mezzadra, Riccardo ^c   Chmielowski, Bartosz ^a,b   Ruchalski, Kathleen ^a   Shintaku, I Peter ^a   Sanchez, Phillip J ^a   Puig Saus, Cristina ^a   Cherry, Grace ^a   Seja, Elizabeth ^a   Kong, Xiangju ^a   Pang, Jia ^a   Berent Maoz, Beata ^a   Comin Anduix, Begona ^a,b   Graeber, Thomas G ^a,b   Tumeh, Paul C ^a,b   Schumacher, Ton N M ^c   Lo, Roger S ^a,b   Ribas, Antoni ^a,b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; GAMMA INTERFERON; JANUS KINASE 1; JANUS KINASE 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; B2M GENE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG MECHANISM; GENE DELETION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOSS; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; JAK1 GENE; JAK2 GENE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR REGRESSION; ANTAGONISTS AND INHIBITORS; BIOPSY; DNA SEQUENCE; DRUG RESISTANCE; EXOME; GENE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOTHERAPY; MELANOMA; METABOLISM; MUTATION; RECURRENT DISEASE; SECONDARY; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; BIOPSY; DRUG RESISTANCE, NEOPLASM; EXOME; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; JANUS KINASE 1; JANUS KINASE 2; MELANOMA; MUTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; RECURRENCE; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84983216790     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1604958     Document Type: Article

References (37)

1. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin- 2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 2000; 6: Suppl 1: S11-4.
2. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-7.
3. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: Longterm follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-47.
4. Eroglu Z, Kim DW, Wang X, et al. Long term survival with cytotoxic T lymphocyte- associated antigen 4 blockade using tremelimumab. Eur J Cancer 2015; 51: 2689-97.
5. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33: 1889-94.
6. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-44.
7. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumabrefractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-17.
8. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-9.
9. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30.
10. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.
11. Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315: 1600-9.
12. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-8.
13. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 1991; 87: 284-92.
14. Sucker A, Zhao F, Real B, et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res 2014; 20: 6593-604.
15. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95: 7556-61.
16. Dunn GP, Sheehan KC, Old LJ, Schreiber RD. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 2005; 65: 3447-53.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
18. Wolchok JD, Hoos A, O'dDay S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immunerelated response criteria. Clin Cancer Res 2009; 15: 7412-20.
19. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71.
20. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to BRAF( V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-7.
21. Atefi M, Avramis E, Lassen A, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20: 3446-57.
22. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014; 4: 80-93.
23. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO 1. J Clin Oncol 2011; 29: 917-24.
24. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
25. Krzywinski M, Schein J, Birol I, et al. Circos: An information aesthetic for comparative genomics. Genome Res 2009; 19: 1639-45.
26. Cerami E, Gao J, Dogrusoz U, et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
27. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: A paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15: 563-91.
28. Muller M, Briscoe J, Laxton C, et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 1993; 366: 129-35.
29. Watling D, Guschin D, Muller M, et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 1993; 366: 166-70.
30. Corrales L, Gajewski TF. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine 2016; 77: 245-7.
31. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
32. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613-6.
33. Marvel D, Gabrilovich DI. Myeloidderived suppressor cells in the tumor microenvironment: Expect the unexpected. J Clin Invest 2015; 125: 3356-64.
34. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
35. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60.
36. Ribas A. Adaptive immune resistance: How cancer protects from immune attack. Cancer Discov 2015; 5: 915-9.
37. Fish EN, Platanias LC. Interferon receptor signaling in malignancy: A network of cellular pathways defining biological outcomes. Mol Cancer Res 2014; 12: 1691-703.